

1

Financial Disclosures

- RegenexBio: Consultant/Advisor
- Notal Vision: Consultant/Advisor
- Regeneron: Consultant/Advisor
- Ocular Therapeutix: Consultant/Advisor

2

Implementation Strategies Practice strategy Phased Implementation Prepare to appeal Resp current on coding Monitor payer policies

Outline – Emerging and Evolving Tech







1. PDT Laser

2. Home OCT

3. Photobiomodulation (PBM)

1

Photodynamic Therapy



- Previously Practices Purchased the Equipment
- Newer Lasers Offer Click Fee per use
- Challenges:
 - \$854 Click Fee Per Treatment
 - \$276 Novitas Reimbursement
- Solution
- Charge Patients Click Fee

5

Photodynamic Therapy



Business Challenges:

- Awareness of when Advanced Beneficiary Notices (ABN) should be used
- Educate the companies on billing limitations
- Advocacy to reimbursement increases where appropriate



Home OCT





 Dosing Regimen: PRN, Fixed, Treat & Extend/Maintain

 Newer Regimen: Treat with Home Monitoring?

- Reimbursement (Category 3):
- Carrier Priced
- 0604T initial device set-up (labor)
- 0605T remote surveillance with support (equip)
- 0606T professional component for interpretation

7

Home OCT







- Potentially reduce visits for patients
- Help with any real/perceived retina specialist shortages

Challenges

- As category 3 code carrier priced (or not covered depending on the carrier)
- With continued use likely to progress to a category 1 code – increased easy of use

8

Photobiomodulation





- LumiThera Lightsite IIII Completed
- Other products: Diopsys ERG, Dark adaptation
- FDA authorization granted November 4, 2024
- Treatment for Dry AMD
- Regimen: 9 treatments repeated every 4 months
- Mean gain of 5.4 letters Treat vs 3.0 letters Untreated
- Vas Sadda Article in JAMA:
 - Differences in Age of Groups, Placebo Effect, Reversion to Mean, Trial Size, Drop Out Rates, etc



Photobiomodulation	
	Reimbursement Issues Category 3 Code (0936T) Cost of Laser vs Click fee approach Inability to use ABN once this is a covered diagnosis